A61K 31/557
Eicosanoids
Official title: Eicosanoids, e.g. leukotrienes {or prostaglandins}
A61K31/557 (Eicosanoids) appears on 1,551 US grants and 2,043 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,551
- Published applications
- 2,043
- Assignees
- 758
- Inventors
- 2,794
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 6 | 0 |
| 1977 | 9 | 0 |
| 1978 | 10 | 0 |
| 1979 | 2 | 0 |
| 1980 | 6 | 0 |
| 1981 | 6 | 0 |
| 1982 | 11 | 0 |
| 1983 | 9 | 0 |
| 1984 | 4 | 0 |
| 1985 | 6 | 0 |
| 1986 | 10 | 0 |
| 1987 | 8 | 0 |
| 1988 | 4 | 0 |
| 1989 | 22 | 0 |
| 1990 | 12 | 0 |
| 1991 | 18 | 0 |
| 1992 | 32 | 0 |
| 1993 | 32 | 0 |
| 1994 | 23 | 0 |
| 1995 | 20 | 0 |
| 1996 | 34 | 0 |
| 1997 | 38 | 0 |
| 1998 | 37 | 0 |
| 1999 | 35 | 0 |
| 2000 | 39 | 0 |
| 2001 | 54 | 16 |
| 2002 | 54 | 63 |
| 2003 | 43 | 78 |
| 2004 | 27 | 67 |
| 2005 | 17 | 71 |
| 2006 | 17 | 60 |
| 2007 | 19 | 67 |
| 2008 | 15 | 53 |
| 2009 | 20 | 70 |
| 2010 | 34 | 59 |
| 2011 | 29 | 67 |
| 2012 | 44 | 90 |
| 2013 | 46 | 104 |
| 2014 | 71 | 133 |
| 2015 | 63 | 107 |
| 2016 | 68 | 106 |
| 2017 | 65 | 94 |
| 2018 | 62 | 75 |
| 2019 | 50 | 101 |
| 2020 | 58 | 91 |
| 2021 | 59 | 112 |
| 2022 | 49 | 91 |
| 2023 | 44 | 73 |
| 2024 | 39 | 85 |
| 2025 | 46 | 56 |
| 2026 | 25 | 54 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Use of high molecular weight hyaluronic acid as ocular transporting vehicle22 Sep 2026US 12,741,027 B2I. Com Medical GmbH
- Compositions for the treatment of glaucoma and ocular hypertension8 Sep 2026US 12,728,131 B2Nicox S A.
- Margaric acid decreases PIEZ02-mediated pain25 Aug 2026US 12,714,688 B2The United States of Americas, as represented by The Secretary, Dept. of Health and Human Services
- Lyophilized preparation of prostaglandin E1 methyl ester for injection and production and use thereof18 Aug 2026US 12,708,604 B2Xi'an Hanfeng Pharmaceutical Co., Ltd.
- Methods and compositions for the treatment of hair loss4 Aug 2026US 12,697,334 B2Aneira Pharma, Inc.
- Combination therapy for pulmonary hypertension8 Oct 2026US 2026/0306461 A1Vivus, Inc.
- Misoprostol formulation for non-oral administration8 Oct 2026US 2026/0306508 A1Conceptra Biosciences, LLC
- Plasmin-induced internal limiting membrane digestion facilitates donor retinal ganglion cell transplantation8 Oct 2026US 2026/0306549 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Ophthalmic solutions for canine, feline & equine glaucoma and oht1 Oct 2026US 2026/0294797 A1
- Rock inhibitors and uses thereof1 Oct 2026US 2026/0297033 A1Alcon Inc.
Most cited
By later US patents
- Means to achieve sustained release of synergistic drugs by conjugation378US 6,051,576 AUniversity of Kentucky Research Foundation · 2000
- Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma296US 4,599,353 AThe Trustees of Columbia University in the City of New York · 1986
- Propylene glycol diester solutions of PGE-type compounds278US 4,409,239 ASyntex (U.S.A.) Inc. · 1983
- Carbonate diester solutions of PGE-type compounds277US 4,410,545 ASyntex (U.S.A.) Inc. · 1983
- Carbonate diester solutions of PGE-type compounds270US 4,328,245 ASyntex (U.S.A.) Inc. · 1982